le 28 avril/April 2023

	The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.

	Listing and disclosure documents will be available at&nbsp;<a href="https://thecse.com/en/listings/diversified-industries/alpha-cognition-inc">www.thecse.com</a>&nbsp;on the trading date.

	Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

	__________________________

	Les actions ordinaires et les bons de souscription d'Alpha Cognition Inc. ont été approuvés pour inscription à la CSE.

	Les documents d'inscription et d'information seront disponibles sur <a href="https://thecse.com/fr/inscriptions/societes-diversifiees/alpha-cognition-inc">www.thecse.com</a> à la date de négociation.

	Alpha Cognition Inc. est une société biopharmaceutique au stade clinique qui se consacre au développement de traitements pour les patients souffrant de maladies neurodégénératives, telles que la maladie d'Alzheimer et les troubles cognitifs avec traumatisme cérébral léger ("mTBI"), pour lesquels il n'existe actuellement aucune option de traitement approuvée. ALPHA-1062, est une nouvelle entité chimique brevetée en cours de développement en tant qu'inhibiteur de l'acétylcholinestérase de nouvelle génération pour le traitement de la maladie d'Alzheimer, avec des effets secondaires gastro-intestinaux minimes attendus. Le métabolite actif de l'ALPHA-1062 se différencie du donépézil et de la rivastigmine en ce qu'il se lie aux récepteurs nicotiniques neuronaux, notamment le sous-type alpha-7, qui est connu pour avoir un effet positif sur la cognition. ALPHA-1062 est également développé en association avec la mémantine pour traiter la démence d'Alzheimer modérée à sévère, et en tant que formulation intranasale pour les troubles cognitifs avec mTBI.
<table border="1" cellpadding="1" cellspacing="1" >
<tbody>
<tr>
<td >
				Issuer/Émetteur:</td>
<td >
				Alpha Cognition Inc.</td>
</tr>
<tr>
<td >
				Security Type/Titre:</td>
<td >
				Common&nbsp;Shares/Actions&nbsp;ordinaires</td>
</tr>
<tr>
<td >
				Symbol(s)/Symbole(s):</td>
<td >
				ACOG</td>
</tr>
<tr>
<td >
				Number of securities issued and outstanding/&nbsp;Titres&nbsp;émis&nbsp;et en circulation:</td>
<td >
				93 900 664</td>
</tr>
<tr>
<td >
				Number of Securities reserved for issuance/&nbsp;Titres&nbsp;réservés&nbsp;pour&nbsp;émission:</td>
<td >
				59 779 708</td>
</tr>
<tr>
<td >
				CSE Sector/Catégorie:</td>
<td >
				Diversified Industries/Sociétés diversifiées</td>
</tr>
<tr>
<td >
				CUSIP:</td>
<td >
				02074J 20 4</td>
</tr>
<tr>
<td >
				ISIN:</td>
<td >
				CA 02074J 20 4 8</td>
</tr>
<tr>
<td >
				Boardlot/Quotité:</td>
<td >
				500</td>
</tr>
<tr>
<td >
				Trading&nbsp;Currency/Monnaie&nbsp;de&nbsp;négociation:</td>
<td >
				CDN$/$CDN</td>
</tr>
<tr>
<td >
				Listing Date/Date de l’inscription:</td>
<td >
				le 1 mai/May&nbsp;2023</td>
</tr>
<tr>
<td >
				Other Exchanges/Autres&nbsp;marches:</td>
<td >
				N/A</td>
</tr>
<tr>
<td >
				Fiscal Year&nbsp;end /Clôture&nbsp;de&nbsp;l'exercice&nbsp;financier:</td>
<td >
				le 31 December/décembre</td>
</tr>
<tr>
<td >
				Transfer Agent/Agent des&nbsp;transferts:</td>
<td >
				Computershare Investor Services Inc.</td>
</tr>
</tbody>
</table>

	&nbsp;
<table border="1" cellpadding="1" cellspacing="1" >
<tbody>
<tr>
<td >
				Issuer/Émetteur:</td>
<td >
				Alpha Cognition Inc. 1OCT2023 Warrants</td>
</tr>
<tr>
<td >
				Security Type/Titre:</td>
<td >
				Warrants</td>
</tr>
<tr>
<td >
				Listing Date/Date de l’inscription:</td>
<td >
				le 1 mai/May&nbsp;2023</td>
</tr>
<tr>
<td >
				Symbol/Symbole:</td>
<td >
				ACOG.WT</td>
</tr>
<tr>
<td >
				Number of securities issued and outstanding/&nbsp;Titres&nbsp;émis&nbsp;et en circulation:</td>
<td >
				9 602 500</td>
</tr>
<tr>
<td >
				CUSIP:</td>
<td >
				02074J 13 9</td>
</tr>
<tr>
<td >
				ISIN:</td>
<td >
				CA 02074J 13 9 6</td>
</tr>
<tr>
<td >
				Boardlot/Quotité:</td>
<td >
				1000</td>
</tr>
<tr>
<td >
				Exercise Price/Prix ​​d'exercice:</td>
<td >
				CAD $1.75/1,75$</td>
</tr>
<tr>
<td >
				Expiry Date/date d'expiration:</td>
<td >
				le&nbsp;1 octobre/October 2023</td>
</tr>
<tr>
<td >
				Transfer Agent/Agent des&nbsp;transferts:</td>
<td >
				Computershare Trust Company of Canada</td>
</tr>
</tbody>
</table>

	&nbsp;The Exchange is accepting Market Maker applications for ACOG,ACOG.WT. Please email:&nbsp;<a href="mailto:Trading@theCSE.com">Trading@theCSE.com</a>

	If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>

	Pour&nbsp;toute&nbsp;question, pour&nbsp;obtenir&nbsp;de&nbsp;l’information&nbsp;supplémentaire&nbsp;veuillez&nbsp;communiquer&nbsp;avec&nbsp;le service des inscriptions au 416 367-7340 ou par&nbsp;courriel&nbsp;à&nbsp;l’adresse:&nbsp;&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>&nbsp;

Alpha Cognition Inc.

2023-0428 - New Listing - Alpha Cognition Inc. (ACOG,ACOG.WT)

CSE25™

CSE Composite Index®

In this series, we delve deep into the experiences of CSE listed companies, exploring their past successes and future opportunities.

CSE Issuer Spotlight

**Follow us** for the **latest news** from the CSE

 The CSE provides a modern and efficient alternative for companies looking to access the Canadian public capital markets.

The Canadian Securities Exchange (CSE)

Learn how we streamline issuer regulation through enhanced disclosure, practical and effective regulatory oversight, and modern technology.

Listing on the CSE

Learn more about the companies we list and how to get started trading on the CSE.

Investing in Listed Companies

Learn how we lower costs, reduce complexity, and provide market making opportunities for the dealer community.

Trading on the CSE

Whether you’re an investor, business leader, or simply looking to learn more, start your journey with the CSE here.

Get Started

From announcements and market updates to in-depth interviews with company leaders - stay informed with the latest from the CSE.

Latest from the CSE

Discover newly listed companies on the CSE through our series of bite-sized interviews with company leaders.

Get to know our latest listings

Listed Company News

Market Activity

List with the CSE

Find a home for your next big idea.

Frequently Asked Questions

How does being listed on the CSE affect me as a shareholder?

Where do I get information and trade CSE listed securities?

Where can I find an RSS feed for listed company news?

Where is the CSE recognized?

Upcoming Events

join the list

Join our mailing list to receive buy-in notifications

The CSE provides a superior exchange experience by investing in our customers’ success with innovation, dedication, and passion.

Where innovation, passion, and trust intersect

We strive to be the most innovative exchange in Canada. We aim to offer unlimited global access and a customized client-centric experience while delivering the lowest cost of public capital. 

We are Canada's entrepreneurial exchange

The most searched CSE listed companies on thecse.com

Recent Quotes

Get the latest regulatory announcements from the CSE concerning its Listings Policies, Trading Rules and functionality and other important industry developments.

Notices

Get the latest information about new CSE listings, the appointment of Market Makers, market events, and other news.

Bulletins

Stay informed with CSE listed company news, providing transparency and accountability to shareholders and the public.

Company News

Stay Informed

The **total volume** traded on the CSE today is

Connect with our professionals and listing experts at industry events and conferences.